While these documents are directed towards the discovery of therapeutic candidates for Alzheimer's disease, they often include inhibition data against the paralogue BACE2 even thought this is not currently considered a drug target. Here, BACE2 is linked to early-onset autosomal dominant Alzheimer disease.